Alzheimer's disease (AD) stands as the predominant form of dementia, presenting significant
and escalating global challenges. Its etiology is intricate and diverse, stemming from a …

The ɛ4 allele of the apolipoprotein E gene (APOE), which translates to the APOE4 isoform,
is the strongest genetic risk factor for late-onset Alzheimer disease (AD). Within the CNS …

Microglia are central players in Alzheimer's disease pathology but analyzing microglial
states in human brain samples is challenging due to genetic diversity, postmortem delay and …

Genetic and experimental evidence suggests that Alzheimer's disease (AD) risk alleles and
genes may influence disease susceptibility by altering the transcriptional and cellular …

Therapeutic antibodies have been developed to target amyloid-beta (Aβ), and some of these
slow the progression of Alzheimer's disease (AD). However, they can also cause adverse …

Alzheimer's disease (AD) is the most common neurodegenerative disorder, characterized
pathologically by extracellular deposition of β-amyloid (Aβ) into senile plaques and …

Recent discoveries of rare variants of human APOE may shed light on novel therapeutic
strategies for Alzheimer's disease (AD). Here, we highlight the newly identified protective …

The targeting of amyloid-beta (Aβ) plaques therapeutically as one of the primary causes of
Alzheimer's disease (AD) dementia has been an ongoing effort spanning decades. While …

The major genetic risk factor for Alzheimer's disease (AD), APOE4, accelerates beta-amyloid
(Aβ) plaque formation, but whether this is caused by APOE expressed in microglia or …

The greatest risk factor for neurodegeneration is the aging of the multiple cell types of
human CNS, among which microglia are important because they are the “sentinels” of …